

HER2/neu IHC

 PATIENT
 REPORT DATE
 BOOKING ID

 Supinder Singh
 11 May 2019
 #011905060353

Human Epidermal Growth Factor Receptor 2 Immunohistochemistry

Test Description

Test is useful for determining overexpression of HER2 protein of gastric and esophageal adenocarcinoma in formalin-fixed, paraffinembedded tissue sections (with reflex to FISH testing).

Clinical Information

Human epidermal growth factor receptor 2 (HER2), is a proto-oncogene located on chromosome 17q21 that encodes a transmembrane protein with tyrosine kinase activity, a member of the HER receptor family and is involved in signal transduction pathways, leading to cell growth and differentiation. Amplification and overexpression of the HER2 gene have been associated with a shorter disease-free survival and shorter overall survival in gastric and gastroesophageal junction cancers, as well as breast, endometrial, and ovarian cancer.

Specimen

Sample Type: FFPE Block S-1493-19

Site: Omentum

Pathology ID: MOLQ/IHC-26052019 **Disease**: Carcinoma Appendix

Scoring

The scoring system is based on type and origin of tumor.

Score	Staining Pattern	Interpretation
0	No staining or <10% of cells	Negative
1+	Faint incomplete staining of cell	Negative
	membrane in >10% of Tumor cells.	
2+	Weak to moderate complete staining of	Weak Positive/
	cell membrane > 10% of Tumor cells.	Equivocal
3+	Strong complete staining of cell	Strong Positive
	membrane in >10% of Tumor cells.	

Interpretation

Results are reported as positive (3 + HER2 protein expression), equivocal (2+), or negative (0 or 1+).

Equivocal (2+) cases will automatically reflex to FISH testing at an additional charge.

Methodology

Immunostaining for HER2 protein was done using PathnSitu Rabbit Anti-Human HER2 monoclonal (Clone EP3) antibody (#PR047)

References

- 1. Rosai and Ackerman's Surgical Pathology.
- 2. NCCN Guidelines Journal of the National Comprehensive Cancer Network 2006 4
- 3. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer guideline validation and development of standardized immunohistochemical testing. Virchows Arch. Sep; 457 (3):299–307
- Brandon S et al. HER2/neu Testing in Gastric Cancer by Immunohistochemsitry. Arch Pathol Lab Med 2014 138
- Ramin Azarhoosh et al. HER2/neu gene amplification in gastric adenocarcinoma and its relationship with clinical and pathological findings. J Gastrointest Oncol. 2017 8:6

Human Epidermal Growth Factor Receptor 2 (HER2/neu): Negative (Score 0)

Microscopy Evaluation

HE Staining (Figure 1)

Tumor cells: 30%

Her2/neu by IHC: Negative (Score 0)

Percentage of cells with uniform membrane staining: 00% (Figure 2)

HE Stained Section




Figure 1

HER2/Neu IHC-Tumor




Figure 2

Reviewed By

Dr. Gulshan Yadav, MD Head, Pathology